2. Search Result
Search Result
Results for "

LAG-3–MHC-II interaction

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99156
    Relatlimab
    3 Publications Verification

    BMS-986016

    		 LAG-3 Cancer
    Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
    Relatlimab
  • HY-P99027
    Ieramilimab

    LAG525; IMP701; Hu5A8

    		 LAG-3 Cancer
    Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
    Ieramilimab
  • HY-176814
    LAG-3-IN-1

    		LAG-3 Cancer
    LAG-3-IN-1 (Compound 11) is a LAG-3 inhibitor with a KD of 0.41  μM. LAG-3-IN-1 disrupts the LAG-3/MHCII interaction, enhances IFN-γ secretion and promotes tumor cell killing in cocultures of PBMCs and cancer cells. LAG-3-IN-1 can be used for cancers like ovarian cancer, colon adenocarcinoma and melanoma research .
    LAG-3-IN-1
  • HY-164308
    SA-15-P

    		LAG-3 Inflammation/Immunology
    SA-15-P inhibits LAG-3/MHCII and LAG-3/FGL1 interactions with IC50 values of 4.21 and 6.52 μM respectively. LAG-3/MHCII interaction is a target for immunotherapies .
    SA-15-P
  • HY-181685
    LAGi-DEL

    		LAG-3 TNF Receptor Cancer
    LAGi-DEL is a LAG-3 inhibitor, with Kd values of 97.33 nM and 271 nM in surface plasmon resonance (SPR) assay and microscale thermophoresis (MST) assay, respectively. LAGi-DEL blocks the LAG-3/MHC-II interaction, with an EC50 of 138 nM. LAGi-DEL restores T cell activation, enhances IFN-γ secretion and promotes immune-mediated cytotoxicity. LAGi-DEL can be used in the research of acute myeloid leukemia, lung cancer and melanoma .
    LAGi-DEL

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: